{"id":5365,"date":"2019-06-27T13:06:40","date_gmt":"2019-06-27T07:36:40","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5365"},"modified":"2023-06-14T11:42:34","modified_gmt":"2023-06-14T06:12:34","slug":"pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi","title":{"rendered":"Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS; AbbVie buys Allergan"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\" id=\"h-sanifit-raises-usd-80-9-m-to-advance-calciphylaxis-pipeline\"><strong>Sanifit raises USD 80.9 M to advance Calciphylaxis Pipeline<\/strong><\/h4>\n\n\n\n<p><strong>Sanifit<\/strong>, a clinical-stage biopharmaceutical company, has raised USD 80.9 million ( \u20ac72.2 million ) in total private fundraising. The financing mainly consisted led by Spain\u2019s Caixa Capital Risc, along with many new investors, including Columbus Venture Partners and Alta Life Sciences. The proceeds raised will help <strong>Sanifit<\/strong> to advance further the clinical development of its lead candidate SNF472 for the treatment of calcific uremic arteriolopathy (CUA), also known as Calciphylaxis. <strong>Calciphylaxis <\/strong>therapeutic market is expected to change at a CAGR rate of 4.13%  for the forecast period of 2019-28. The anticipated launch of Sodium thiosulfate (Hope Pharmaceuticals) and SNF472 (Sanifit), for the treatment of Calciphylaxis, is going to accelerate the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/calciphylaxis-market\" class=\"ek-link\">Calciphylaxis market outlook<\/a><\/strong>.  <\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-first-ever-treatment-for-chronic-rhinosinusitis-with-nasal-polyps-approved\"><strong>First ever treatment for chronic rhinosinusitis with nasal polyps approved  <\/strong><\/h4>\n\n\n\n<p> The U.S. Food and Drug Administration today approved the combined drug of Regeneron and Sanofi, <strong>Dupixent <\/strong>(dupilumab), for the treatment of nasal polyps accompanied by <strong>chronic rhinosinusitis<\/strong> in adults. <strong>Chronic Rhinosinusitis<\/strong> (<strong>CRS<\/strong>), an inflammatory condition of the nose and sinuses, is a common medical condition that affects about 11% of adults in Europe and about 12% of adults in the United States. The Chronic <a href=\"https:\/\/www.delveinsight.com\/report-store\/rhinosinusitis-epidemiology-forecast\">Rhinosinusitis <\/a>with <a href=\"https:\/\/www.delveinsight.com\/report-store\/nasal-polyps-market\">Nasal Polyps <\/a>(CRSwNP) treatment options is limited. However, various other drugs, still not yet approved include omalizumab, and mepolizumab significantly reduces nasal polyp burden.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-abbvie-acquires-allergan-for-usd-63-b\"><strong>AbbVie acquires Allergan for USD 63 B<\/strong><\/h4>\n\n\n\n<p><strong>AbbVie <\/strong>is all set to acquire Irish Botox maker, <strong>Allergan <\/strong>for <strong>USD 63 Billion<\/strong>. The combined firm will comprise various franchises with positions across immunology, haematologic oncology, medical aesthetics, neuroscience, women\u2019s health, eye care and virology. The acquisition will help Allergan to enhance its product portfolio- expected to grow at high-single-digit annual growth rate from more than $30 billion in 2020- a through AbbVie&#8217;s commercial strength, expertise and international infrastructure.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanifit raises USD 80.9 M to advance Calciphylaxis Pipeline Sanifit, a clinical-stage biopharmaceutical company, has raised USD 80.9 million ( \u20ac72.2 million ) in total private fundraising. The financing mainly consisted led by Spain\u2019s Caixa Capital Risc, along with many new investors, including Columbus Venture Partners and Alta Life Sciences. The proceeds raised will help [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5118,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[56,70,2068,1892,4799,4798,1510,2072,533],"industry":[17225],"therapeutic_areas":[17278],"class_list":["post-5365","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbvie","tag-allergan","tag-calciphylaxis","tag-chronic-rhinosinusitis","tag-dupixent","tag-nasal-polyps","tag-regeneron-pharmaceuticals","tag-sanifit","tag-sanofi","industry-pharmaceutical","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS<\/title>\n<meta name=\"description\" content=\"FDA approves Dupixent (dupilumab) for the treatment of Chronic rhinosinusitis (CRS), which is the first ever treatment so far to be available in CRS market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS\" \/>\n<meta property=\"og:description\" content=\"FDA approves Dupixent (dupilumab) for the treatment of Chronic rhinosinusitis (CRS), which is the first ever treatment so far to be available in CRS market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-06-27T07:36:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T06:12:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS","description":"FDA approves Dupixent (dupilumab) for the treatment of Chronic rhinosinusitis (CRS), which is the first ever treatment so far to be available in CRS market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi","og_locale":"en_US","og_type":"article","og_title":"Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS","og_description":"FDA approves Dupixent (dupilumab) for the treatment of Chronic rhinosinusitis (CRS), which is the first ever treatment so far to be available in CRS market.","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-06-27T07:36:40+00:00","article_modified_time":"2023-06-14T06:12:34+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi","url":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi","name":"Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","datePublished":"2019-06-27T07:36:40+00:00","dateModified":"2023-06-14T06:12:34+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"FDA approves Dupixent (dupilumab) for the treatment of Chronic rhinosinusitis (CRS), which is the first ever treatment so far to be available in CRS market.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-sanifit-abbvie-allergan-sanofi#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","width":647,"height":345,"caption":"Business cocktail"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Allergan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Calciphylaxis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">chronic rhinosinusitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dupixent<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nasal polyps<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanifit<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">Allergan<\/span>","<span class=\"advgb-post-tax-term\">Calciphylaxis<\/span>","<span class=\"advgb-post-tax-term\">chronic rhinosinusitis<\/span>","<span class=\"advgb-post-tax-term\">Dupixent<\/span>","<span class=\"advgb-post-tax-term\">Nasal polyps<\/span>","<span class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Sanifit<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jun 27, 2019","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Jun 27, 2019 1:06 pm","modified":"Updated on Jun 14, 2023 11:42 am"},"featured_img_caption":"Business cocktail","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5365"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5365\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5118"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5365"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5365"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}